Table 2.

Multivariate analysis of the effect of UBE2C mRNA expression on disease-free survival (DFS), distant metastasis-free survival (DMFS), and overall survival (OS) in patients with HR+/HER2– breast cancer.

		DFS			DMFS			OS
		Hazard ratio	95% C.I.	P-value	Hazard ratio	95% C.I.	P-value	Hazard ratio	95% C.I.	P-value
All
Gene expression
UBE2C	(Low vs. high)	2.35	1.51–3.66	<0.001	2.19	1.38-3.49	<0.001	2.58	1.53–4.34	<0.001
Clinical variable
ER (IHC)	(pN0 vs. pN1)	2.15	1.35–3.41	0.001	2.46	1.49–4.04	<0.001	2.59	1.51–4.45	<0.001
	(pN0 vs. pN2&3)	2.59	1.61–4.19	<0.001	3.00	1.79–5.02	<0.001	2.95	1.70–5.11	<0.001
Tumor size	(≤2 cm vs. >2 cm)	1.22	0.81–1.85	0.338	1.15	0.74–1.78	0.543	1.11	0.70–1.76	0.660
Histologic grade	(I&II vs. III)	1.20	0.82–1.77	0.351	1.26	0.84–1.90	0.262	1.52	0.99–2.32	0.053
pN0
Gene expression
UBE2C	(Low vs. high)	3.26	1.41–7.54	0.006	2.76	1.11–6.85	0.029	4.32	1.27–14.68	0.019
Clinical variable
Tumor size	(≤2 cm vs. >2 cm)	1.39	0.71–2.74	0.336	1.30	0.62–2.74	0.486	1.64	0.72–3.74	0.238
Histologic grade	(I&II vs. III)	0.93	0.43–1.98	0.845	1.34	0.61–2.95	0.469	1.96	0.86–4.46	0.108
pN1
Gene expression
UBE2C	(Low vs. high)	2.75	1.30–5.84	0.008	2.53	1.18–5.42	0.017	3.67	1.50–9.00	0.005
Clinical variable
Tumor size	(≤2 cm vs. >2 cm)	1.24	0.64–2.43	0.525	1.16	0.58–2.32	0.683	0.76	0.37–1.55	0.447
Histologic grade	(I&II vs. III)	1.03	0.53–2.04	0.921	0.97	0.47–1.98	0.928	1.11	0.52–2.35	0.786
pN2/N3
Gene expression
UBE2C	(Low vs. high)	1.44	0.70–2.97	0.319	1.49	0.70–3.19	0.300	1.31	0.61–2.82	0.492
Clinical variable
Tumor size	(≤2 cm vs. >2 cm)	0.99	0.44–2.24	0.980	0.87	0.38–1.99	0.744	1.08	0.44–2.61	0.871
Histologic grade	(I&II vs. III)	1.54	0.82–2.87	0.176	1.46	0.76–2.79	0.254	1.65	0.84–3.24	0.148

pN, lymph node status; CI, confidence interval.

Bold indicate significant values.